TYRA
Tyra Bioscience, Inc · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website yra.bio
- Employees(FY) 38
- ISIN US90240B1061
Performance
-25.13%
1W
-23.91%
1M
-18.39%
3M
-8.01%
6M
+18.56%
YTD
+28.28%
1Y
Profile
Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Technical Analysis of TYRA 2024-11-04
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-04 06:27
Daily – Vickers Top Buyers & Sellers for 11/04/2024(Argus Research)
- 2024-11-03 08:45
- 2024-10-28 07:00
- 2024-10-27 19:00
- 2024-10-25 12:39
- 2024-10-24 18:05
- 2024-10-23 16:05
- 2024-10-23 04:05
- 2024-10-22 21:07
- 2024-10-22 17:18
- 2024-10-20 09:00
- 2024-10-18 14:34
- 2024-10-18 06:56
- 2024-10-18 03:05
- 2024-10-16 01:01
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc(GuruFocus.com)
- 2024-10-11 08:00
- 2024-10-10 20:00
- 2024-09-26 08:52
- 2024-09-19 08:15
- 2024-09-11 16:05
- 2024-09-11 04:05
- 2024-09-10 16:47
Tyra Biosciences Names Doug Warner Chief Medical Officer(MT Newswires)
- 2024-09-10 16:05
- 2024-09-10 04:05
- 2024-09-09 09:55
- 2024-08-27 19:50
- 2024-08-15 07:23
- 2024-08-08 09:29
- 2024-08-07 16:05
- 2024-08-07 11:54
TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024(Investorplace)
Page 1 of 4
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.